Synthetic Air
Phase 2Small molecule
Synthetic Air is one of 22 small molecule programs targeting Paralysis. It is currently in Phase 2.
1
Indications
1
Total Trials
0
Active Trials
21
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
32 competitors in Paralysis
#DrugCompanyPhaseTrials
1Prostigmin
Merck & Co.Approved
Robinul
Alnylam PharmaceuticalsApproved
Bridion
CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Approved
Relistor
SSalix
Approved
Naropin
FFresenius Kabi Oncology Ltd.
Approved
Dulcolax
Boehringer IngelheimApproved
Movantik
AAveritas Pharma, Inc.
Approved
Polyethylene Glycols
JJinnah Postgraduate Medical Centre
Approved
Minocin
TTriax
Phase 3
Senna
MMedtronic - MITG
Approved
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Synthetic Air. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 2[1]
- Company
- QQueen's University